Nyrada to Commence Phase Ia Clinical Trial

Highlights:
•Nyrada receives Human Research Ethics Committee (HREC) approval to initiate first-in-human Phase Ia clinical trial.
•Trial will evaluate the safety and tolerability of NYR-BI03 in healthy human volunteers.
•Volunteer recruitment to begin shortly, with the first dosing anticipated by the end of March 2025.
•Final Phase Ia trial readout expected in 3QCY2025.